Chione Ltd. 13D and 13G filings for Acrivon Therapeutics, Inc. Common Stock:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-07-10 8:34 pm Unchanged | 2024-06-30 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV | Chione Ltd. | 3,848,632 12.500% | 0 (Unchanged) | Filing |
| 2024-07-10 8:29 pm Sale | 2023-12-31 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV | Chione Ltd. | 3,848,632 17.300% | -7,965 (-0.21%) | Filing |
| 2022-11-28 3:59 pm Purchase | 2022-11-17 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV | Chione Ltd. | 3,856,597 18.500% | 3,856,597 (New Position) | Filing |